Altimmune, Inc. (ALT)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
ALT raises $225 million selling stock and warrants to fund development
# 🧾 What This Document Is This is a **prospectus supplement**, a legal filing that adds the specific details of a new stock offering to a previously approved "shelf" registration. Think of it like a detailed menu addendum for a restaurant that already has a general license to serve food. 👉 In si
Altimmune files for capital raise citing MASH and ALD drug candidate success
# 🧾 What This Document Is 📑 This document is a Preliminary Prospectus Supplement, filed on April 22, 2026. Essentially, it is a detailed legal roadmap informing investors about the company and the specific securities Altimmune, Inc. plans to sell. Since it is a "preliminary" document, it means the
SEC filings
All filings →Insider trades
All insider trades →Altimmune, Inc. has no reported insider trades in the last 90 days.